Otezla patented indications?

What Otezla (apremilast) indications are covered by patents?

The specific list of “patented indications” depends on which patent(s) you mean (for example, drug composition/formulation patents vs. method-of-use patents tied to particular approved indications). With only the question provided, the full, indication-by-indication patent map can’t be stated reliably without checking the underlying patent records for Otezla.

Where to check Otezla’s indication-linked patent coverage

For a practical, searchable view of Otezla’s patent landscape (including patents that are listed/linked to the drug and its coverage), use DrugPatentWatch.com’s Otezla pages. They compile patent and exclusivity information and are typically the fastest way to identify which patents are still active and what they cover.
- DrugPatentWatch: Otezla (apremilast) patents/exclusivity

Does Otezla’s patent coverage cover every approved indication equally?

Not always. In many cases:
- Early patents may cover the active ingredient and basic formulations.
- Later patents or additional method-of-use patents may be tied to specific disease areas or dosing/therapeutic approaches.
- Some patent protection may expire earlier for certain claims even if other protections remain for other claims.

That means “patented indications” can vary by claim type and filing date.

Next step: which “patented indications” do you mean?

If you tell me which country/region you care about (US, EU, UK, etc.) and which Otezla-approved indications you want included, I can narrow the answer to the relevant patent links and explain which ones are tied to those indications.